Compare Novartis AG (NVS) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs State Street PDR S&P Retail ETF — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while State Street PDR S&P Retail ETF trades at $86.52 (market cap $402.57M). The key difference: Novartis AG is far larger — about 680.6× State Street PDR S&P Retail ETF's market cap, and Novartis AG pays a 3.31% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| NVS | XRT | |
|---|---|---|
Market Cap | $274.00B | $402.57M |
Volume | 1,852,137 | 2,586,736 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $92.35 |
52-Week Low | $121.80 | $77.28 |
Typical Hold Time | 82 Days | 44 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
XRT, the SPDR S&P Retail ETF, trades at $82.91, down 0.05% on the day, with a bearish technical signal from moving averages. The ETF faces headwinds from higher interest rates and inflation pressuring consumer spending, as reflected in mixed retail sales data. Recent news highlights holiday sales projections exceeding $1 trillion but also notes analyst expectations of underperformance versus the S&P 500 into 2027.
The outlook for XRT is cautious due to macroeconomic pressures on retail, though potential Fed easing could offer relief. Risks include consumer sentiment volatility and competitive shifts. Analyst sentiment is neutral to bearish, with institutional interest shown via options activity but no strong bullish consensus for near-term outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
